Johnson & Johnson ($JNJ) Stock Forecast: Up 2.8% Today

What is Johnson & Johnson?

Johnson & Johnson (JNJ) is a multinational corporation known for its healthcare products, pharmaceuticals, and medical devices. It has a diverse portfolio across various sectors, including oncology and neurological treatments. The overall market sentiment is positive towards JNJ today, with a strong bullish movement.

Why is Johnson & Johnson going up?

JNJ stock is up 2.8% on Jan 13, 2026 15:40

• JNJ's bullish movement could be attributed to the company's announcement of adding 500 jobs at a new plant in North Carolina, focusing on oncology and neurological treatments. This expansion signifies growth and commitment to domestic manufacturing, which investors view positively.
• The performance of Pfizer in the oncology sector and AbbVie's recent deals with the Trump administration might have also contributed to the positive sentiment in the healthcare sector, indirectly benefiting JNJ as a major player in the industry.
• Investors may be optimistic about the healthcare sector as a whole, considering the focus on research and development, manufacturing investments, and pricing agreements that aim to boost innovation and accessibility to key medicines.
• Overall, the bullish movement in JNJ's stock today could be a reflection of both company-specific developments, such as the new plant expansion, and broader industry trends towards innovation and growth.

JNJ Price Chart

JNJ Technical Analysis

JNJ News

Inside Pfizer's Oncology Performance Ahead of Q4 Results

This article analyzes Pfizer's oncology segment ahead of its Q4 results, highlighting the strength of its cancer drug portfolio and the impact of the Seagen acquisition. It discusses expected sales drivers and declines for key drugs like Xtandi, Lorbrena, and Ibrance, and also provides a competitive landscape of other major players in the oncology space such as AstraZeneca, Merck, J&J, and Bristol-Myers. The piece concludes with an overview of Pfizer's stock performance, valuation, and earnings estimates.

https://www.theglobeandmail.com/investing/markets/stocks/PFE/pressreleases/37018189/inside-pfizers-oncology-performance-ahead-of-q4-results/

J&J To Add 500 Jobs at New Plant, Doubling Down on North Carolina

Johnson & Johnson announced plans to add 500 jobs in Wilson, North Carolina, by building a second production plant. This new drug product manufacturing facility, focused on oncology and neurological treatments, is part of J&J's $55 billion commitment to U.S. manufacturing and R&D. The company aims for all advanced medicines used in the U.S. to be manufactured domestically, boosting employment and supply chain resilience.

https://www.biospace.com/business/j-j-to-add-500-jobs-at-new-plant-doubling-down-on-north-carolina

AbbVie Gets Tariff Relief, Pledges $100 Billion, Lower Prices For Key Medicines

AbbVie announced a voluntary agreement with the Trump administration to provide lower prices on Medicaid, expand direct-to-patient offerings for key medicines, and pledge $100 billion in U.S.-based research and development and capital investments over the next decade. In return, AbbVie will receive a three-year exemption from tariffs and future pricing mandates. In separate but related news, AbbVie also entered into an exclusive licensing agreement with RemeGen for RC148 and agreed to acquire a device manufacturing facility from West Pharmaceutical Services.

https://www.benzinga.com/markets/large-cap/26/01/49871428/abbvie-gets-tariff-relief-pledges-100-billion-lower-prices-for-key-medicines

AbbVie inks MFN drug pricing deal, pledges $100bn to US R&D

AbbVie has signed a Most Favored Nation (MFN) drug pricing deal with the Trump administration, becoming the 16th big pharma company to do so. As part of the agreement, AbbVie will offer certain immunology, ophthalmology, and metabolic health medications at reduced prices through Medicaid and TrumpRx.gov and has committed $100 billion to expanding its US R&D capacity over the next decade. This move aims to allow the company to move beyond policies that harm American innovation and includes investments in both R&D and manufacturing.

https://www.pharmaceutical-technology.com/news/abbvie-mfn-us-drug-pricing-deal-trump-randd-commitment/

AbbVie Stock Rises After $100 Billion Deal With Trump. It Will Avoid Tariffs.

AbbVie's stock rose after the company announced a deal with the Trump administration. The agreement involves AbbVie cutting drug prices and investing $100 billion in U.S. research over the next decade. In return, the drugmaker will receive an exemption from certain tariffs.

https://www.barrons.com/articles/abbvie-stock-trump-tariffs-deal-4f08ec87?gaa_at=eafs&gaa_n=AWEtsqdzfmAtJgnw6GyiW9da6V_ldaUh7jlkBYXpeZVMmJzBNDARb0D3d2tm&gaa_ts=69662ee5&gaa_sig=CF6OQ55Snhyyx-1zHUqaCfXnMYtWAI5iFUdlqR-fckrPveouDi3PUw9vLIa_SqK_WlHD5P4o-li1yKeXunSM3g%3D%3D

Trending Today

fuboTV Inc. ($FUBO) Stock Forecast: Down 22.9% Today

Teladoc Health Inc. ($TDOC) Stock Forecast: Down 8.5% Today

Amplitude Inc. ($AMPL) Stock Forecast: Down 12.7% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 7.0% Today

Academy Sports and Outdoors, Inc. ($ASO) Stock Forecast: Up 5.3% Today

Fastly Inc. ($FSLY) Stock Forecast: Down 10.3% Today

C3.ai Inc. ($AI) Stock Forecast: Down 7.7% Today

TripAdvisor Inc. ($TRIP) Stock Forecast: Down 7.1% Today

Shoals Technologies Group Inc. ($SHLS) Stock Forecast: Up 5.4% Today

WEX Inc. ($WEX) Stock Forecast: Down 5.1% Today

Johnson & Johnson Price History

01.03.2025 - JNJ Stock was down 5.3%

• The bearish movement in JNJ stock could be attributed to the announcement from Nanobiotix regarding the first data from a Phase 1 study evaluating NBTXR3 as a therapy for patients with locally advanced NSCLC. This news might have caused some investors to shift their focus towards the potential of this new therapy, leading to a temporary sell-off of JNJ shares.
• The discussion around finding high-growth dividend stocks could have also influenced investor sentiment, with some possibly reallocating their investments based on the perceived growth potential of other dividend stocks.
• Overall, the market movement in JNJ today seems to be driven by a combination of factors related to potential competition in the healthcare sector and the search for high-growth opportunities in dividend stocks.

02.00.2026 - JNJ Stock was up 1.2%

• JNJ's choice to maintain its quarterly dividend at $1.30 per share for the first quarter of 2026 is likely a contributing factor to the positive market sentiment.
• Recent strategic acquisitions, including Halda Therapeutics, and FDA approvals for its medical technologies and treatments have enhanced investor confidence in JNJ's growth prospects.
• Analysts have raised price targets for JNJ following these events, signaling an optimistic outlook for the company's performance and potential future returns.
• Developments related to Pfizer's transformation and AbbVie Inc.'s decrease in stock holdings may have indirectly affected investor interest in JNJ, underscoring the competitive environment in the healthcare and pharmaceutical sector.

07.00.2025 - JNJ Stock was up 2.5%

• JNJ stock closed at $144.62 with a +0.89% change from the previous close.
• Smart money is seen to bet big on JNJ options, reflecting a positive outlook on the stock.
• Speculation on JNJ surpassing earnings expectations is contributing to the bullish trend.
• Investors are viewing JNJ favorably amidst market downturns, indicating it as a stable investment in the current economic climate.

07.00.2025 - JNJ Stock was up 2.0%

• The strong bullish movement in JNJ is believed to be influenced by smart money activities in JNJ options, reflecting a positive sentiment from wealthy investors.
• The bearish strategy utilized by these investors might have bolstered confidence in the stock, resulting in a rise in its value.
• The notable surge in JNJ options points towards a general optimism among market participants regarding the company's future prospects, thereby contributing to today's bullish trend in the stock.

13.00.2026 - JNJ Stock was up 2.8%

• JNJ's bullish movement could be attributed to the company's announcement of adding 500 jobs at a new plant in North Carolina, focusing on oncology and neurological treatments. This expansion signifies growth and commitment to domestic manufacturing, which investors view positively.
• The performance of Pfizer in the oncology sector and AbbVie's recent deals with the Trump administration might have also contributed to the positive sentiment in the healthcare sector, indirectly benefiting JNJ as a major player in the industry.
• Investors may be optimistic about the healthcare sector as a whole, considering the focus on research and development, manufacturing investments, and pricing agreements that aim to boost innovation and accessibility to key medicines.
• Overall, the bullish movement in JNJ's stock today could be a reflection of both company-specific developments, such as the new plant expansion, and broader industry trends towards innovation and growth.

05.00.2026 - JNJ Stock was down 1.3%

• The bearish movement in JNJ's stock price could be attributed to the halt of a Phase IIb trial for JNJ-95475939, a bispecific antibody for atopic dermatitis, after it failed to meet efficacy expectations. This development might have raised concerns among investors about the company's pipeline and future growth prospects in the dermatology segment.
• Despite being highlighted as one of the AI-powered medical stocks for a strong portfolio in 2026, the setback in the eczema trial could have overshadowed the positive outlook, leading to a bearish sentiment towards JNJ.
• The global rosacea market's projected growth and advancements in AI-powered medical stocks, including JNJ, may have initially created a positive sentiment, but the specific news regarding the failed trial likely had a more immediate and negative impact on the stock price.
• Investors might be closely monitoring JNJ's strategic decisions in dermatology, especially with the focus shifting towards other candidates and acquisitions after the setback with JNJ-95475939, to assess the company's ability to innovate and maintain its competitive edge in the healthcare sector.

15.09.2024 - JNJ Stock was up 2.8%

• Johnson & Johnson reported impressive Q3 earnings with both revenue and EPS beating expectations, driven by strong sales of cancer drugs.
• The revision of annual outlook to reflect the V-Wave acquisition also contributed to the positive sentiment surrounding the stock.
• Analysts revising their forecasts ahead of the earnings call and high-rolling investors positioning themselves bullish on JNJ further added to the optimism in the market.
• The overall positive earnings report and strategic acquisitions seem to have fueled investor confidence, leading to the bullish movement in Johnson & Johnson's stock price today.

16.06.2025 - JNJ Stock was up 5.9%

• JNJ raised its FY2025 earnings guidance, leading to a surge in its stock price.
• The company's Q2 earnings beat estimates, with an increase in revenue, which further boosted investor confidence.
• With the broader market showing signs of rebound, investors are turning to defensive positions like medical stocks, including JNJ, ahead of their Q2 reports.
• The focus on AI-driven medical device stocks, including JNJ, indicates a growing interest in innovative healthcare technologies, potentially contributing to the positive market sentiment around the company.

16.06.2025 - JNJ Stock was up 5.4%

• JNJ stock experienced a strong bullish movement today.
• The bullish trend can be attributed to JNJ's Q2 earnings report exceeding expectations, with an EPS of $2.77 and a revenue increase of 5.8% to $23.74 billion.
• The raised 2025 adjusted EPS forecast and sales outlook further boosted investor confidence in the company's performance.
• Analysts and investors may have been impressed by JNJ's strategic positioning in the healthcare sector, especially considering the defensive nature of medical stocks in uncertain market conditions.

10.06.2025 - JNJ Stock was up 1.9%

• JNJ stock showed a positive movement today, possibly reflecting optimistic market sentiment and investor confidence.
• Speculations of surpassing earnings predictions have influenced the upward trend, suggesting robust financial performance and growth opportunities for the company.
• The disclosure of regulatory alignment and a recent patent application for JNJ-1900 by Nanobiotix could have also uplifted investor confidence, hinting at potential progress in cancer treatment.
• Backed by a track record of exceeding earnings expectations and favorable market conditions, JNJ continues to attract investors interested in promising returns within the healthcare sector.

22.07.2025 - JNJ Stock was down 0.6%

• J&J's bearish movement today could be attributed to the potential drug import tariffs proposed by the government, leading to uncertainty and negative sentiment among investors.
• The sale of J&J stock by Representative Thomas Kean might have also contributed to the downward pressure on the stock, as large sell-offs by insiders can sometimes signal lack of confidence in the company's future performance.
• Despite recent developments, J&J's commitment to investing $2 billion in its U.S. manufacturing operations could be seen as a positive long-term move, potentially enhancing its production capabilities and competitiveness in the market. However, the immediate market reaction seems to be influenced more by the tariff threats and insider selling.

01.03.2025 - JNJ Stock was down 5.4%

• The downward trend in JNJ's stock price today is associated with the repeated dismissal of using bankruptcy to resolve talc cancer claims. This legal setback suggests potential financial risks and uncertainties for the company.
• JNJ's choice to contest talc lawsuits instead of settling has reversed $7 billion in legal reserves, indicating a shift in their legal approach that investors may perceive as risky.
• The recent disclosure of positive data from a clinical trial by Nanobiotix is unrelated to JNJ's talc lawsuits and is unlikely to have impacted the bearish movement in JNJ's stock today.
• Concerns about the lasting effects of the ongoing talc litigations on JNJ's finances and reputation may be influencing investors, contributing to the bearish market activity.